ProPhase Labs Statistics
Total Valuation
ProPhase Labs has a market cap or net worth of 951,551. The enterprise value is 9.48 million.
| Market Cap | 951,551 |
| Enterprise Value | 9.48M |
Important Dates
The last earnings date was Friday, March 27, 2026.
| Earnings Date | Mar 27, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
ProPhase Labs has 9.52 million shares outstanding. The number of shares has increased by 314.85% in one year.
| Current Share Class | 9.52M |
| Shares Outstanding | 9.52M |
| Shares Change (YoY) | +314.85% |
| Shares Change (QoQ) | +432.42% |
| Owned by Insiders (%) | 3.49% |
| Owned by Institutions (%) | 2.23% |
| Float | 9.18M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.19 |
| PB Ratio | 0.19 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -0.71 |
| EV / Sales | 1.93 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.11, with a Debt / Equity ratio of 1.76.
| Current Ratio | 0.11 |
| Quick Ratio | 0.04 |
| Debt / Equity | 1.76 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -2.65 |
Financial Efficiency
Return on equity (ROE) is -359.06% and return on invested capital (ROIC) is -121.47%.
| Return on Equity (ROE) | -359.06% |
| Return on Assets (ROA) | -16.64% |
| Return on Invested Capital (ROIC) | -121.47% |
| Return on Capital Employed (ROCE) | -208.14% |
| Weighted Average Cost of Capital (WACC) | 52.34% |
| Revenue Per Employee | 51,042 |
| Profits Per Employee | -139,083 |
| Employee Count | 96 |
| Asset Turnover | 0.08 |
| Inventory Turnover | 4.88 |
Taxes
In the past 12 months, ProPhase Labs has paid 624,000 in taxes.
| Income Tax | 624,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -96.43% in the last 52 weeks. The beta is -0.32, so ProPhase Labs's price volatility has been lower than the market average.
| Beta (5Y) | -0.32 |
| 52-Week Price Change | -96.43% |
| 50-Day Moving Average | 0.13 |
| 200-Day Moving Average | 2.17 |
| Relative Strength Index (RSI) | 45.20 |
| Average Volume (20 Days) | 184,265 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.19 |
Income Statement
In the last 12 months, ProPhase Labs had revenue of 4.90 million and -13.35 million in losses. Loss per share was -1.57.
| Revenue | 4.90M |
| Gross Profit | 1.94M |
| Operating Income | -16.74M |
| Pretax Income | -21.37M |
| Net Income | -13.35M |
| EBITDA | -11.91M |
| EBIT | -16.74M |
| Loss Per Share | -1.57 |
Balance Sheet
The company has 90,000 in cash and 8.62 million in debt, with a net cash position of -8.53 million or -0.90 per share.
| Cash & Cash Equivalents | 90,000 |
| Total Debt | 8.62M |
| Net Cash | -8.53M |
| Net Cash Per Share | -0.90 |
| Equity (Book Value) | 4.90M |
| Book Value Per Share | 0.55 |
| Working Capital | -48.68M |
Cash Flow
| Operating Cash Flow | -8.34M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 4.83M |
| Net Borrowing | 3.31M |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
Gross margin is 39.57%, with operating and profit margins of -341.69% and -272.49%.
| Gross Margin | 39.57% |
| Operating Margin | -341.69% |
| Pretax Margin | -436.16% |
| Profit Margin | -272.49% |
| EBITDA Margin | -243.08% |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
ProPhase Labs does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -314.85% |
| Shareholder Yield | -314.85% |
| Earnings Yield | -1,403.18% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on December 22, 2025. It was a reverse split with a ratio of 0.1.
| Last Split Date | Dec 22, 2025 |
| Split Type | Reverse |
| Split Ratio | 0.1 |
Scores
ProPhase Labs has an Altman Z-Score of -3.2 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -3.2 |
| Piotroski F-Score | 2 |